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ABSTRACT
While infection with influenza A viruses has been extensively investigated, 
infections with influenza B viruses which are commonly categorized into the 
highly homologous Victoria and Yamagata lineages, are less studied, despite their 
considerable virulence. Here we used RT-PCR assays, hemagglutination inhibition 
assays and antibody titers to determine the levels of influenza B infection. We report 
of high influenza B Victoria virus prevalence in the 2015–16 winter season in Israel, 
affecting approximately half of the Israeli population. We further show that the 
Victoria B virus infected individuals of all ages and that it was present in the country 
throughout the entire winter season. The vaccine however included the inappropriate 
Yamagata virus. We propose that a quadrivalent vaccine, that includes both Yamagata 
and Victoria lineages, should be considered for future influenza vaccination. 
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INTRODUCTION
Influenza viruses, which are members of the 
Orthomyxoviridae family, are categorized into three genera 
- A, B, and C [1, 2]. Infections with influenza viruses are 
a major cause of morbidity and mortality worldwide [3–
5]. Indeed, approximately 3–5 million individuals suffer 
from severe illness each year with an estimated 250,000–
500,000 related deaths [6]. The influenza virus undergoes 
rapid and significant changes that prevent the generation 
of long-lasting protective immunity [7, 8]. In attempt to 
prevent infection, the influenza vaccine composition, is 
re-evaluated every year. The trivalent vaccine usually 
contains two influenza A and one influenza B virus. 
Influenza B viruses can be divided into two distinct 
lineages Victoria (denoted B/Victoria/2/87) and Yamagata 
(denoted B/Yamagata/16/88) [9–11]. The two lineages 
are similar and their hemagglutinin proteins show 
approximately 96% homology. New influenza B virus 
strains constantly evolve because the segmented viral 
genome has allowed the genetic reassortment between 
viruses of different lineages during co-infection [12, 13].
The two antigenically and genetically distinct 
influenza B viruses, have been circulating in humans since 
1983. Between 1992 and 2000, Victoria lineage viruses were 
detected only in eastern Asia. From March to September of 
2001 and during the 2001–2002 influenza season, Victoria 
lineage viruses were detected in several countries for the 
first time in a decade [14].
Several studies have demonstrated that influenza 
B infections can be quite dominant in a single season 
or across consecutive seasons [15, 16]. Yet, despite the 
importance of influenza B viruses, much of the published 
scientific literature regarding the epidemiology of 
influenza focused on influenza A. As a result, the global 
               Clinical Research Paper
Oncotarget6624www.impactjournals.com/oncotarget
epidemiology and disease burden of influenza B viruses is 
still poorly understood. 
The influenza trivalent vaccine given in the 2015–16 
season included the A/California/7/2009 (H1N1)-like, 
A/Switzerland/9715293/2013 (H3N2)-like and influenza 
B/Phuket/3073/2013-like (B/Yamagata lineage) viruses. 
Evidence from the southern hemisphere and our 
own observations in Israel (manuscript submitted for 
publication), indicated that the vaccine given in the 2015–16 
season was inefficient, as a significant number of individuals 
were infected with the influenza B and with the pandemic 
influenza viruses [6, 17]. 
The purpose of the current study was to characterize 
the influenza B infection during the 2015–16 season in 
Israel. 
RESULTS
Influenza B virus infection prevalence between 
2011 and 2016
To examine the prevalence of infection by   Yamagata 
and Victoria influenza B lineages, we determined their 
presence in patient samples collected between 2011 and 
2016. Samples were obtained from patients suffering from 
Influenza-like illness (ILI), collected from sentinel clinics 
throughout Israel. In general, the percentages of patient 
samples infected with influenza B viruses varied over the 
years and peaks of influenza B infection were observed in 
the years following those in which influenza B viruses were 
hardly present (Figure 1). In 2011–12 and in 2013–14, 35% 
of all influenza infections were due to influenza B viruses. In 
contrast, in 2012–13 and in 2014–15, influenza B infections 
were detected in only 5% of the patient samples, 
while in the last winter season (2015–16), 50% of the 
influenza-infected individuals were due to influenza B 
(Figure 1). Interestingly, a single influenza B lineage 
dominated in each of the examined winter seasons. In 
2011–12 and in 2015–16, the Victoria lineage was 
dominant, while in 2012–15, the Yamagata lineage was 
responsible for most influenza B infections (Figure 1). 
Analysis of the weekly distribution of Yamagata and 
Victoria influenza B viruses in the 2015–16 season showed 
that these viruses were detectable throughout the winter 
season (Figure 2).
Sero-prevalence of antibodies to Yamagata and 
Victoria viruses 
To test the extent of exposure to Yamagata and 
Victoria viruses in the Israeli population (both symptomatic 
and asymptomatic infection), we conducted a sero-
prevalence study in which we examined sera obtained 
in 2014, when Yamagata lineage was most prevalent 
(Figure 1) and in 2016, when the Victoria lineage was 
most prevalent (Figure 1). No significant differences in 
Yamagata virus antibody titers in 2014 versus 2016 were 
noted (Figure 3A). In contrast, high antibody titers against 
Victoria were observed in 2016 (Figure 3B). These results 
prompted us to quantify the percentages of individuals 
having anti-Yamagata and anti-Victoria antibodies in 
2014 and in 2016. Strikingly, while the percentage 
of individuals carrying antibodies against Yamagata 
was not significantly different between 2014 and 2016 
(Figure 4A), 45% more individuals had anti-Victoria 
antibodies in 2016 as compared to 2014 (Figure 4B). 
Figure 1: Prevalence of influenza B infections in Israel between 2011 and 2016. The presence of Yamagata and Victoria 
influenza B lineages, in community patients with ILI. 
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Figure 2: Weekly distribution of influenza B infection. The graph demonstrates the weekly distribution of influenza B Yamagata 
and Victoria lineages detected in community ILI patients in 2015–16.
Figure 3: Prevalence of antibodies against Yamagata and Victoria in 2014 and 2016. Seropositivity against Yamagata (A) and 
Victoria (B) in 2014 and in 2016 in serum, samples stored in the Israel National Serum Bank established by the Israel Center for Disease Control.
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This observation indicates that at least 45% of the 
population was infected with influenza B Victoria in the last 
winter season.
Finally, we analyzed the age distribution of the 
influenza-infected individuals. As presented in Figure 
5, anti-Yamagata antibodies were detected in all age 
groups, in a relatively large percentages of the population 
examined in both 2014 and in 2016 (Figure 5A). Although 
anti-Victoria antibodies were detected in all age groups in 
both seasons, the percentages of individuals expressing 
anti-Victoria antibodies was higher in 2016 as compared 
to 2014 (Figure 5B).
DISCUSSION
Accurate determination of the prevalence of specific 
lineages of circulating influenza viruses provides public 
health officials with information required to evaluate 
vaccination programs and allocate resources. The data also 
aid in the design of more effective vaccines and can assess 
whether immunity against one particular strain is effective 
against another influenza virus strain.
Following assessments of the 2000–02 influenza 
infection profiles, when the Victoria lineage became 
predominant worldwide [14], the World Health 
Organization recommended use of strain B/Hong 
Kong/330/2001 (Victoria lineage) in the vaccine of 
2002–2003 [18, 19]. It was reported that in the southern 
hemisphere, some individuals were infected with the 
influenza/B Victoria virus. Here, we report that in the 
2015–16 winter season, 45% of the Israeli population were 
infected with influenza B Victoria virus. In the last winter 
season, approximately 1.7 million individuals (20% of 
the population), 60.4% whom were above the age of 65, 
were vaccinated with the seasonal influenza vaccine in 
Israel. Approximately 90% of them received the trivalent 
vaccine, and 10% received the quadrivalent vaccine. 
These data, along with the reported high prevalence of 
Victoria virus infections, suggest that the current vaccine 
is not effective against the influenza B/Victoria lineage. It 
is possible that some individuals infected with influenza 
B/Victoria were asymptomatic but were involved in 
transmitting the infection as suggested by Hsu et al., [20] 
and as observed for asymptomatic children infected with 
H1N1 in Taiwan [20, 21].
The level of cross-protection between the two B 
lineages is assumed to be low. Few reports have shown 
that infection with the Yamagata lineage influenza 
B virus may induce cross-lineage antibody response 
against the Victoria lineage as well, however, infection 
with the Victoria lineage fails to provide adequate 
protection [22–24].
Studies in the United States have shown that the 
frequent influenza B vaccine mismatches of recent years 
have been associated both with substantial increases 
in infection, hospitalizations and deaths [25], and with 
high influenza-related medical costs [26, 27]. Thus, 
considering the findings presented here, we recommend 
use of a quadrivalent influenza vaccine that contains the 
two influenza B lineages. 
MATERIALS AND METHODS
Clinical samples
Nasopharyngeal and serum samples were used for 
our evaluation. Nasopharyngeal samples were collected as 
part of the community influenza surveillance conducted in 
collaboration with the Israel Center for Disease Control 
(ICDC). These samples were collected from over 20 
outpatient clinics, from 1919 patients presenting with 
influenza-like illness (ILI) during the influenza season 
spanning between October 2015 and April 2016. 
Serum samples (N = 1,018) were obtained from 
the Israel National Serum Bank established by the Israel 
Center for Disease Control. The samples were collected 
Figure 4: Prevalence of antibodies against Yamagata and Victoria in the entire population. Presence of antibodies to 
Yamagata (A) and Victoria (B) influenza B viruses in 2014 and in 2016 in serum samples.
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from individuals in 2014 and in 2016. Details regarding 
age groups, gender and geographical region of residence 
in Israel were available to the researchers and patient 
identity was kept anonymous. Samples from patients 
suffering from immunological disorders were not included 
in the study. 
Viral genome extraction and real-time PCR 
analysis (q-PCR and q-RT-PCR)
Viral genome was extracted from 500 µl of patient 
Nasopharyngeal samples using the NucliSENS easyMAG 
kit (BioMerieux, France), and eluted in 55 µl elution 
buffer. All samples were stored at –70oC. Sentinel samples 
from community patients were tested for the presence of 
influenza viruses (A, B, and H1N1pdm) and respiratory 
syncytial virus (RSV), by qRT-PCR as previously described 
[28, 29].
Determination of influenza B lineages
To determine the influenza B lineage (Yamagta and 
Victoria), all influenza B-positive samples were subjected 
to a second round of qRT-PCR, performed using one set of 
primers and two different probes, as previously described 
[30]. The qRT-PCR reactions were performed in 25 µl 
Ambion Ag-Path Master Mix (Life Technologies, USA) 
using TaqMan Chemistry on the ABI 7500 instrument.
Hemagglutination inhibition assay
All patient sera were treated with receptor destroying 
enzyme (RDE) (Sigma C8772, diluted 1:4), for 16 h 
prior to heat inactivation (30 min, 56°C). Absorption 
with erythrocytes was performed to remove non-specific 
hemagglutination, in accordance with a modified WHO 
protocol [31]. Serial two-fold dilutions (1:20–1:2560) of 
sera in 25 μl PBS were prepared in V-shaped well plates, 
and an equal volume of four hemagglutinin (HA) units of 
viral antigen was added. The mixture was then incubated 
at room temperature for 1 h. Fifty microliters of 0.5% 
chicken erythrocytes suspended in PBS, were added to the 
wells, and mixed by shaking the plates on a mechanical 
vibrator. Agglutination patterns were read after 30 min 
and the hemagglutination inhibition (HI) titer was defined 
as the reciprocal of the last dilution of serum that fully 
inhibited hemagglutination. The cut-off value selected 
for a positive result was 1:40. The influenza B antigens 
Figure 5: Age distribution of seropositivity against Yamagata and Victoria. Age distribution of seropositivity to Yamagata (A) 
and Victoria (B) influenza B in 2014 and in 2016.
Oncotarget6628www.impactjournals.com/oncotarget
(B/Brisbane/60/2008- Victoria and B/Massachusetts/2/2012 
–Yamagata) were supplied by the WHO. 
Statistical analysis
The Chi-square test was applied to evaluate the 
differences in percent positivity between the compared 
groups. A p value < 0.05 was considered statistically 
significant. All analyses were performed using SPSS 
(version 21.0.0. SPSS Inc., Chicago, IL, USA), SAS (SAS 
9.1, SAS Institute Inc, Cary, NC, USA) and Excel software.
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